REVIEW PAPER
Recommendations of the Polish Paediatric Society, the Polish Society of Vaccinology, and the Polish Society of Family Medicine on meningococcal vaccinations in children and adults in Poland
1
Department of Paediatrics with Medical Assessment Unit, Medical University of Warsaw, Warsaw, President of the Polish Society of Vaccinology, Poland
2
Department of Paediatrics of the College of Medical Sciences, University of Rzeszow, Rzeszow, Poland
3
Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland
4
Department of Community Medicine and Public Health, Medical University of Warsaw, Warsaw, Poland
5
Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland
6
Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland
7
Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland
8
Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; National Consultant in Family Medicine, President of the Polish Society of Family Medicine, Poland
9
Department of Paediatrics, Paediatric Oncology and Immunology, Pomeranian Medical University, Szczecin; President of the Polish Paediatric Society, Poland
10
Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland; National Consultant in Paediatrics
Submission date: 2022-12-04
Acceptance date: 2023-01-04
Publication date: 2022-12-30
Pediatr Pol 2022;97(4):279-289
KEYWORDS
TOPICS
ABSTRACT
Invasive meningococcal disease is a dangerous bacterial infection that often leads to death or permanent disability. Immunization is the best strategy to protect individuals against invasive infections caused by Neisseria meningitidis. The effectiveness of vaccines has been demonstrated in many countries where they have been introduced into national vaccination programs.
Meningococcal vaccinations in Poland are recommended in the framework of the National Immunization Program. However, they are not reimbursed, meaning the patient or parent covers vaccination costs. In addition, insufficient public awareness of the disease course and risks associated with meningococcal infection, the need for immunization in the first year of a child’s life, the number of doses administered, and the price of the vaccines are barriers to the acceptance and implementation of meningococcal immunization, especially in the youngest children.
Recommendations for physicians implementing meningococcal vaccination in children and adults are the result of the work of an expert group.
Meningococcal vaccinations in Poland are recommended in the framework of the National Immunization Program. However, they are not reimbursed, meaning the patient or parent covers vaccination costs. In addition, insufficient public awareness of the disease course and risks associated with meningococcal infection, the need for immunization in the first year of a child’s life, the number of doses administered, and the price of the vaccines are barriers to the acceptance and implementation of meningococcal immunization, especially in the youngest children.
Recommendations for physicians implementing meningococcal vaccination in children and adults are the result of the work of an expert group.
REFERENCES (52)
2.
Skoczyńska A, Gołębiewska A, Wróbel-Pawelczyk I, et al. [In:] Inwazyjna choroba meningokokowa (IChM) w Polsce w 2021 roku. Dane KOROUN 2022.
3.
Campbell H, Parikh SR, Borrow R, Kaczmarski E, Ramsay ME, Ladhani SN. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill 2016; 21: 30175.
4.
Skoczyńska A, Gołębiewska A, Wróbel-Pawelczyk I, et al. Inwazyjna choroba meningokokowa (IChM) w Polsce w 2018 roku. Dane KOROUN 2019.
5.
Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367: 397-403.
7.
Muzzi A, Brozzi A, Serino L, et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine 2019; 37: 991-1000.
8.
Frosi G, Biolchi A, Sapio ML, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013; 31: 4968-4974.
9.
Waśko I, Gołębiewska A, Kiedrowska M, et al. Genetic variability of Polish serogroup B meningococci (2010–2016) including the 4CMenB vaccine component genes. Vaccine 2020; 38: 1943-1952.
10.
Waśko I, Hong E, De Paola R, et al. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland. Vaccine 2016; 34: 510-515.
11.
Donald RGK, Hawkins JC, Hao L, et al. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum Vaccin Immunother 2017; 13: 255-265.
12.
Trumenba – charakterystyka produktu leczniczego (24 maja 2022). https://www.ema.europa.eu/en/d....
13.
Borrow R, Taha MK, Giuliani MM, Pizza M, Banzhoff A, Bekkat- Berkani R. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J Infect 2020; 81: 862-872.
14.
Martinón-Torres F, Banzhoff A, Azzari C, et al. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. J Infect 2021; 83: 17-26.
15.
Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. Lancet Child Adolesc. Heal. 2018, 2, 395-403. 10.1016/S2352-4642(18)30103-2.
16.
Kent A, Beebeejaun K, Braccio S, et al. Safety of meningococcal group B vaccination in hospitalised premature infants. Arch Dis Child Fetal Neonatal Ed 2019; 104: F171-F175.
17.
Bexsero – charakterystyka produktu leczniczego (25 luty 2022). https://www.ema.europa.eu/en/d....
18.
Ladhani SN, Campbell H, Andrews N, et al. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced national surveillance, England. Clin Infect Dis 2021; 73: e1661-e1668.
19.
Marshall HS, Richmond PC, Nisse, MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013; 31: 1569-1575.
20.
Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomised, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J 2016; 35: 673-682.
21.
Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med 2017; 377: 2349-2362.
22.
Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12: 597-607.
23.
Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J 2016; 35: 548-554.
24.
Fiorito TM, Baird GL, Alexander-Scott N, et al. Adverse events following vaccination with bivalent rLP2086 (Trumenba®): an observational, longitudinal study during a college outbreak and a systematic review. Pediatr Infec Dis J 2018; 37: e13-e19.
25.
Duffy J, Marquez P, Dores GM, et al. Safety surveillance of bivalent meningococcal group B vaccine, vaccine adverse event reporting system, 2014–2018. Open Forum Infect Dis 2020; 7: ofaa516.
26.
Christensen H, Ma M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 853-861.
27.
Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med 2020; 382: 318-327.
28.
Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Heal 2007; 12: 1409-1421.
29.
Campbell H, Edelstein M, Andrews N, Borrow R, Ramsay M, Ladhani S. Emergency meningococcal ACWY vaccination program for teenagers to control group W meningococcal disease, England, 2015–2016. Emerg Infect Dis 2017; 23: 1184-1187.
30.
Campbell H, Andrews N, Parikh SR, et al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Heal 2022; 6: 96-105.
31.
Nimenrix – charakterystyka produktu leczniczego (24 maja 2022). https://www.ema.europa.eu/en/d....
32.
Villena R, Valenzuela MT, Bastías M, Santolaya ME. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine 2019; 37: 6915-6921.
33.
Villena R, Valenzuela MT, Bastías M, Santolaya ME. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction. Vaccine 2022; 40: 666-672.
35.
Jaca A, Mathebula L, Iweze A, Pienaar E, Wiysonge CS. A systematic review of strategies for reducing missed opportunities for vaccination. Vaccine 2018; 36: 2921-2927.
36.
Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 2010; 23: 740-780.
37.
Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence 2014; 5: 98-126.
38.
Safadi MAP, Martinon-Torres F, Weckx LY, et al. Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: a post-hoc analysis in a phase 3b, randomised, controll. Vaccine 2019; 37: 4858-4863.
39.
Zafack JG, Bureau A, Skowronski DM, De Serres G. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open 2019; 9: e026953.
40.
Findlow J, Bai X, Findlow H, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine 2015; 33: 3322-3330.
41.
Pereira P, Benninghoff B, Moerman L. Systematic literature review on the Safety and immunogenicity of rotavirus vaccines when co-administered with meningococcal vaccines. Hum Vaccin Immunother 2020; 16: 2861-2872.
42.
Ruiz García Y, Sohn WY, Seib KL, et al. Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect. Vaccines 2021; 6: 130.
43.
Martinón-Torres F, Bernatowska E, Shcherbina A, et al. Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function. Pediatrics 2018; 142: e20174250.
44.
Joint Committee on Vaccination and Immunisation. Immunisation against infectious Disease. Green Book 17.05.2022.
45.
Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunisation schedules: a randomised controlled trial. JAMA 2012; 307: 573-582.
46.
Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomised controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum. Vaccin Immunother 2014; 10: 1993-2004.
47.
Shen J, Bouée S, Aris E, Emery C, Beck EC. Long-term mortality and state financial support in invasive meningococcal disease – real-world data analysis using the French National Claims Database (SNIIRAM). Infect Dis Ther 2022; 11: 249-2621.
48.
Beck E, Klint J, Garcia S, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine 2020; 38: 7558-7568.
49.
Burman C, Serra L, Nuttens C, Presa J, Balmer P, York L. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum Vaccines Immunother 2019; 15: 459-469.
50.
Lahra MM, Enriquez RP, Hogan TP. Australian Meningococcal Surveillance Programme annual report, 2018. Commun Dis Intell 2020; 44.
51.
Knol MJ, Ruijs WLM, Antonise-Kamp L, de Melker HE, van der Ende A. Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018. Euro Surveill 2018; 23.
52.
Pivette M, Taha MK, Barret AS, et al. Targeted vaccination campaigns of teenagers after two clusters of B invasive meningococcal disease in Brittany, France, 2017. BMC Public Health 2020; 20: 1-9.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
